Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Xencor (NASDAQ:XNCR) Inc on Friday, setting a price target of $52, which is approximately 41.96% above the present share price of $36.63.
Goldstein expects Xencor Inc to post earnings per share (EPS) of -$0.61 for the fourth quarter of 2020.
The current consensus among 8 TipRanks analysts is for a Strong Buy rating of shares in Xencor, with an average price target of $43.
The analysts price targets range from a high of $52 to a low of $21.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $13.09 million and a net profit of -$37.6 million. The company's market cap is $2.1 billion.
According to TipRanks.com, Mizuho Securities analyst Mara Goldstein is currently ranked with 1 stars on a 0-5 stars ranking scale, with an average return of -1.3% and a 36.54% success rate.
Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.